Completed PHASE2 INTERVENTIONAL 4-arm NCT01434134

Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA)

Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: A Randomized, Placebo-controlled, 2x2 Factorial, Double Blind Trial of Candesartan and Metoprolol

Sponsor: AstraZeneca

Conditions Breast Cancer Heart Failure

Interventions Candesartan Metoprolol Placebo

Updated 5 times since 2017 Last updated: Oct 21, 2014 Started: Sep 30, 2011 Primary completion: Sep 30, 2014 Completion: Sep 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01434134, this PHASE2 trial focuses on Breast Cancer and Heart Failure and remains completed. Sponsored by AstraZeneca, it has been updated 5 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Norwegian Cancer Society
University Hospital, Akershus
University of Oslo

Data source: University Hospital, Akershus

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lørenskog, Norway